SLC5A2 and type 1 diabetes mellitus: Global clinical T1D trials have been conducted to examine additional indications for the use of SGLT2 inhibitors, including canagliflozin [5], dapagliflozin [6,7,8], empagliflozin [9], and sotagliflozin (a dual SGLT1/2 inhibitor) [10,11,12], for individuals with T1D.